Quanterix Corporation announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer?s disease (AD) diagnosis. These relationships further the company?s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix?s leading blood biomarker assays. Collectively AdventHealth, Mass General Brigham, Mayo Clinic, South Carolina Alzheimer'sDisease Research Center (SC-ADRC) at the Medical University of South Carolina, and UPMC represent 140+ hospitals across 18 states, caring for approximately 21 million patients in their hospital networks.

This reach will provide greater access to patients for high-accuracy, non-invasive AD testing. Quanterix can enable health systems to access Alzheimer?s blood biomarker tests through a variety of models, including sample processing through Lucent Diagnostics, Quanterix?s diagnostic testing brand, or by installing Simoa technology in-house to develop and validate their own Laboratory Developed Tests (LDTs). Blood-based biomarker testing offers Alzheimer?s patients a non-invasive method and greater access to AD testing overall.

Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD. This approach is not only burdensome and invasive for patients, but also costly, making them unsuitable for most primary and secondary care settings1. This inaccessibility has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting quality of life, medical autonomy, and general wellbeing1.

With 15 million Americans predicted to be affected by Alzheimer?s by 2060,2 high-accuracy, easily accessible blood testing will play a critical role in early detection and treatment of Alzheimer?s. Quanterix?s Simoa p-Tau 217 assays provide high accuracy, consistent with the recommendations in the recent NIA-AA criteria for Alzheimer?s diagnosis3, stating that p-Tau 217 is the only plasma biomarker appropriate for Alzheimer?s diagnosis. Quanterix?s commitment to establishing the industry standard for accuracy continues to position the company as a critical partner for AD testing. Beyond these five health systems, Quanterix is initiating partnerships with reference laboratories and hospitals globally to enable patients with cognitive symptoms consistent with Alzheimer?s disease to be tested.